GlassScriptPhysician profile
Stella K Milos
NPI 1154303147
$3,379.39
in general payments reported to CMS, 2019-2025
21 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $374 · 2021: $688 · 2022: $291 · 2023: $520 · 2024: $655 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.36 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $446.20 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $277.99 | 2023-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $248.66 | 2019-2022 | |
| Lilly USA, LLC | $241.16 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $219.70 | 2021-2025 | |
| Novo Nordisk INC | $217.91 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.06 | 2019-2025 | Jardiance |
| Pfizer INC. | $152.43 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $127.12 | 2020-2023 | Verquvo |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Novartis Pharmaceuticals Corporation | $104.23 | 2021-2025 | |
| Exact Sciences Corporation | $98.15 | 2023-2025 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $56.14 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.15 | 2020-2024 | Xifaxan, Trulance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.80 | 2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $43.38 | 2023 | |
| Amarin Pharma, INC. | $32.46 | 2020 | |
| Sumitomo Pharma America, INC. | $28.63 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Milos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.